Products - Chronic kidney disease | Topic

Showing 10 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sibeprenlimab for treating IgA nephropathy [ID6604]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atrasentan for treating primary IgA nephropathy [ID6558]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for treating primary IgA nephropathy [ID6703]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Obinutuzumab for treating primary membranous nephropathy [ID6751]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [GID-TA12008]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zibotentan–dapagliflozin for treating chronic kidney disease with proteinuria [TSID12423]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Chronic kidney disease Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 10 products

Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]

Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]

Sibeprenlimab for treating IgA nephropathy [ID6604]

Atrasentan for treating primary IgA nephropathy [ID6558]

Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]

Ravulizumab for treating primary IgA nephropathy [ID6703]

Obinutuzumab for treating primary membranous nephropathy [ID6751]

Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [GID-TA12008]

Zibotentan–dapagliflozin for treating chronic kidney disease with proteinuria [TSID12423]

Chronic kidney disease Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 10 products

Status
1 selected